Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594511 | 0.89 | DPP4 (0.39) | JAK2JAK1CCR3DPP4TRPV4 | |
| SCHEMBL14177522 | 0.81 | DPP4 (0.36) | JAK1DPP4TRPV4CYP11B1CYP11B2 | |
| SCHEMBL714646 | 0.80 | JAK2 (0.40) | JAK2JAK1CCR3TP53BRD4 | |
| Ammonia Solution, Strong SCHEMBL1763973 | 0.79 | JAK2 (0.39) | JAK2JAK1CCR3TP53BRD4 | |
| SCHEMBL13404350 | 0.75 | JAK2 (0.37) | JAK2JAK1CCR3TRPV4CYP11B1 | |
| SCHEMBL3600694 | 0.70 | CCR5 (0.40) | — | |
| SCHEMBL16447914 | 0.68 | MEN1 (0.45) | JAK2JAK1 | |
| SCHEMBL5634958 | 0.67 | NSD3 (0.46) | JAK2JAK1 | |
| SCHEMBL17856438 | 0.65 | GAA (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL5634461 | 0.63 | CCR5 (0.48) | TP53BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099708-A1 | Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099708-A1 | Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099708-A1 | Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| EP-2091946-A1 | PIPERIDINE DERIVATIVE USED FOR TREATING CHEMOKINE RECEPTOR 5 MEDIATED DISEASES | AstraZeneca AB (SE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008071927-A1 | PIPERIDINE DERIVATIVE USED FOR TREATING CHEMOKINE RECEPTOR 5 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071927-A1 | PIPERIDINE DERIVATIVE USED FOR TREATING CHEMOKINE RECEPTOR 5 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
| US-20080139612-A1 | Chemical Compound | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139612-A1 | Chemical Compound | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139612-A1 | Chemical Compound | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139612-A1 | Chemical Compound | CCR5, CCR2, CXCR3 | JAK2 40/4885JAK1 155/4885CCR3 9/4885 |
| US-20100099708-A1 | Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases | CCR5, CXCR5, CCR2 | JAK2 191/4885JAK1 860/4885CCR3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.